We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · February 25, 2021

Association of Immunophenotype With pCR to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

JAMA Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Oncology
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial
JAMA Oncol 2021 Feb 18;[EPub Ahead of Print], OM Filho, DG Stover, S Asad, PJ Ansell, M Watson, S Loibl, CE Geyer, J Bae, K Collier, M Cherian, J O'Shaughnessy, M Untch, HS Rugo, JB Huober, M Golshan, WM Sikov, G von Minckwitz, P Rastogi, D Maag, N Wolmark, C Denkert, WF Symmans

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading